Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
The cancer types were breast, ovarian, colon, pancreatic, gastric, glioblastoma.
The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company’s cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells.
These results pave the way for a possible antitumor treatment which the company will further examine. Moreover, the differential efficacy of different cannabinoids emphasizes the need for personalized diagnostics – and the data obtained serves this purpose.
Itamar Borochov, CEO of Cannabics Pharmaceuticals said: “The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine”.